My Dementia Avoidance Protocol - Please improve it and offer advice

Indeed - on my video about immunizations - the big benefit is keeping someone from having a major inflammatory response as that injures all organs, but it seems like the brain is quite susceptible.

So I do recommend pretty much all the vaccines. I suspect with Covid, if you take Paxlovid early - probably just a good.

My experience thus far with patients on Rapamycin has been pretty favorable in regard to not getting horribly unwell with viral illnesses. Considering doing a similar protocol to the TRIIM trial to improve T cell immunity also should be on the plate as folks get older.

On @Steve_Combi 's article, yes, I have patients positive for Beta Amyloid 42:40 ratio and p-Tau 217 with no symptoms or very vague MCI. It is something to track to see if interventions are working and improving these test results, or slowing predicted worsening in these values over time. This is where the DORA agents are interesting as they have been linked with decrease in the isoforms of Beta Amyloid - but not necessarily the ratio we track.

7 Likes

Dr. Fraser, Would you please share your opinion of Paraspinal Etanercept. There are some studies showing that it can reverse MCI/early AD. It is approved for rheumatoid arthritis but is starting to be used off label (not approved by the FDA) for AD and seems to show promise. Do you think this is worth chasing, and if so, how/where to find a practitioner who would prescribe and inject (into the spinal column). Would appreciate your view –

I think I’ll go with Vera-Health.ai’s review of this … and apart from the expense, you’d have a very hard time finding someone to inject it; and the rationale for paraspinal versus simply subcutaneous makes little sense. This drug gets widely distributed through the body (apparently not crossing the BBB or into the spinal column) slowly, but through lymphatic uptake, which would have it be moving away from the spine anyway.
I think if one were compelled to do this, it would be hard to find a physician to prescribe it for this indication given it has more significant risks that anything that I would prescribe that I’d lump into “speculative therapy.” One of my rules for this, is that it has to be very low risk for adverse outcomes.

Clinical evidence for perispinal/paraspinal etanercept in Alzheimer’s disease is limited to uncontrolled human reports and is not supported by randomized controlled trial evidence; it should not be used outside a clinical trial.

Clinical Guideline

Do not offer etanercept (including perispinal/paraspinal administration) to treat Alzheimer’s disease outside research settings because there is no high-quality evidence of clinical benefit and biologic therapy carries meaningful infection risk. 1 I

Human clinical evidence (perispinal/paraspinal etanercept specifically)

  • Open-label case series / uncontrolled reports suggest “rapid improvement,” but are high risk of bias and not confirmatory:
    • Journal of Neuroinflammation (2008): report of rapid cognitive improvement after perispinal etanercept; uncontrolled observational data only, hypothesis-generating. 2 III
    • BMC Neurology (2008): report of rapid improvement in verbal fluency/aphasia after perispinal etanercept; case-based data without randomization/blinding. 3 III
    • Narrative reviews proposing mechanism/clinical paradigm (not efficacy evidence): 4 III; 5 III; 6 III; 7 III; 8 III
  • No randomized, double-blind, placebo-controlled trial evidence supporting perispinal etanercept for AD is provided in the retrieved sources. (The only RCT in AD below used subcutaneous systemic etanercept, not perispinal.)

Human RCT evidence for etanercept in AD (systemic SC, relevant for plausibility and safety, but not perispinal efficacy)

  • Weekly subcutaneous etanercept did not show statistically significant cognitive/global benefit in mild–moderate AD over 24 weeks (small RCT), though tolerability was acceptable:
    • Neurology (2015) double-blind RCT (n=41 randomized) found no statistically significant changes in cognition/behavior/global function; designed primarily for tolerability/safety. 9 I

Mechanistic/PK plausibility for CNS delivery via perispinal route (preclinical)

  • A rat radiolabel study did not find evidence of CNS delivery after perispinal injection, directly challenging the proposed “CSF delivery” rationale:
    • Alzheimer’s Research & Therapy (2015): radiolabeled biologics after perispinal injection in rats; concluded no evidence for CNS delivery. 10 II

Systematic review-level synthesis (TNF inhibitors in AD broadly)

  • Systematic review concludes evidence is limited/heterogeneous and not definitive for TNF-α inhibitors in AD, reinforcing that perispinal etanercept remains unproven:
    • Int J Geriatr Psychiatry (2018) systematic review of TNF-α inhibitors in AD pathology/outcomes. 11 II

Observational epidemiology (risk of incident AD in inflammatory disease; does not test treatment of established AD; not perispinal)

  • Large EHR/case-control signals that TNF inhibitors (including etanercept) are associated with lower AD odds in RA/psoriasis populations are hypothesis-generating and vulnerable to confounding by indication, health-user bias, and outcome misclassification:
    • PLoS ONE (2020) EHR case-control analysis. 12 II
    • RMD Open (2024) systematic review/meta-analysis in RA cohorts suggests lower incident dementia risk with biologic DMARDs/TNF inhibitors. 13 II
    • Gerontology (2025) systematic review/meta-analysis in RA suggests association with lower dementia risk; retrospective evidence only. 14 II

Bottom line for practice

  • Perispinal/paraspinal etanercept for Alzheimer’s disease lacks Level I efficacy evidence and has conflicting mechanistic support; the best available RCT evidence for etanercept in AD (systemic SC) is negative for clinical efficacy, so perispinal use should be considered experimental only. 9 I; 10 II
2 Likes

Thank you so much for your reply.
I guess for now, in addition to “behavior” will stick to lithium, tadalafil, intranasal insulin, and a few other supps like bacopa monnieri --but will continue to explore. MCT oil???

3 Likes

At the recent UC Berkeley longevity conference I spoke to one of the local scientist attendees who mentioned his wife is APOE3/4 and was concerned about her risk, so took a proteomics test provided by the following company: called “Molecular You”. https://www.molecularyou.com/

Here is a link to their website product page. Advanced Biomarker Insights | Biomarker Testing Service Company where they describe their services looking at 190+ biomarkers.

It looks like they charge $1,100 list price for the one time test (and maybe annual subscriptions), which includes a home visit by a phlebotomist to draw blood.

Note these guys DO NOT test for genetic markers like APOE4, but only proteomic ones which would be activated, in theory, as a result of, say, APOE4—but not necessarily if there are other mitigating factors.

The result of the proteomics evaluation was that, despite the E3/4 status, they concluded she was extremely low risk of alzhiemers due to all the positive measures evident from the proteomics test (I think she was in excellent health, regular exerciser, good blood markers, etc. too).

So, perhaps another way to look at your E4 risk profile with greater information.

2 Likes

Anything new on if Rapamycin are still on for many of those SV tech people? If not on, what they opted to? Metformin? GLP1?

1 Like

More good news on rapamycin:

EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial

Carriers of the apolipoprotein E4 (APOE4) allele often develop cerebrovascular dysfunction and broader systemic alterations decades before the onset of Alzheimer’s disease (AD) pathology or clinical symptoms. Early interventions that can improve these functions may help delay or slow AD progression. In this study, we repurposed rapamycin (sirolimus), an FDA-approved medication with anti-aging properties, to target APOE4 associated multisystem dysfunction. We conducted a single arm trial of low dose rapamycin (1 mg/day for 4 weeks) in cognitively normal adults aged 45 to 65 years, prior to detectable AD pathology, stratified by APOE genotype. The primary outcome was cerebral blood flow (CBF), while secondary outcomes included plasma metabolomics, inflammatory cytokines, AD biomarkers, and gut microbiome composition. Twenty-three participants completed the study, including nine APOE4 carriers and fourteen non-carriers. Rapamycin significantly increased CBF in APOE4 carriers, with increases exceeding 15% across multiple brain regions, and improved metabolic and inflammatory profiles with minimal adverse effects. In contrast, non-carriers showed no significant change in CBF and exhibited distinct physiological responses, highlighting genotype dependent effects. These findings suggest that rapamycin may mitigate early cerebrovascular and systemic dysfunction in APOE4 carriers and support a precision medicine approach in which therapeutic response is influenced by genotype.

https://pubmed.ncbi.nlm.nih.gov/42723264/

8 Likes

It is interesting the items that can increase CBF, and the interventions seem more effective in those with an ApoE4.
Aerobic exercise, Strength training, Omega 3 fatty acids, Anserine/Carnosine, Ketogenic diet plus HIIT, Sleep optimization, Nitric oxide optmization, NAD precursors, and for those who have enough blood pressure - ARBs or ACE inhibitors that get into the brain (telmisartan is my favorite), Mediterranean diet … among others. The discussion on hypercapnia and deep breathing also comes into play.
I suspect most of us are doing a combination of many of these.

3 Likes

Bisphosphonates and the risk of dementia in patients with osteoporosis or fragility fracture: A population-based study in Hong Kong

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70503

Pop-sci article:

Common Osteoporosis Drugs Linked to Lower Alzheimer’s Risk in 120,000-Person Study

“Researchers at the University of Hong Kong analyzed electronic medical records from more than 120,000 people age 60 and older. NBP users had a 16% lower risk of developing Alzheimer’s disease and related dementias than untreated patients and a 24% lower risk than people who received other osteoporosis medications.”

3 Likes

This is a fascinating area, given all the controversy of so many of my patients who have no interest in taking things like Fosamax (alendronate) due to all the potential horrible side effects (which are actually significantly overstated).

My first time I appreciated this class as a “longevity medication” outside of simply osteoporosis treatment was this discussion in the European Society of Medicine in 2024, of Geroscience Drugs.

I’m in agreement with the SGLT2’s, GLP’s, Rapamycin … as I go down the rest of their table, I’m not so sure … but the 3rd item, Bisphosphonates … like Fosamax … that was an item I didn’t expect to see. This article adds to my interest in this class.

UpdatedLongevityDrugListPaperFeb2024.pdf (278.0 KB)

3 Likes

Yes, there are threads on here where bisphosphonates as geromodulators were discussed. One of mechanisms that was speculated about was impact on the CV system. So ultimately ACM is lower for folks on these drugs. And yes, they are effective against osteoporosis. You are also right that people are very fearful of these drugs based on exaggerated risk assessments. However, while I am usually pretty immune to such panics, I admittedly find one aspect of these drugs rather disquieting: dental issues. It’s not really about the jaw necrosis - which is rare. Rather something else: apparently, once you’ve been on a course of bisphosphonates, the bones around your teeth are permanently altered, and not for the better. You are stuck for life - and if you anticipate dental issues, which is common as you age, your dental bone health will be compromised going forward, and as an elderly person you have very little room for error when it comes to teeth. That stopped me dead in my tracks - especially that there are probably some dental implants still in my future. So, while I am intrigued by these drugs, I am electing to pass on them for the time being. YMMV.

4 Likes

Well, that’s concerning.

I’m an elderly person who’s been on bisphosphates on and off since 2017. I have no original teeth. Rather, crowns, bridges, and implants. Had lots of dental work done over that period. So far, at least, no indication that bispho’s had any negative effect. N of 1 of course. YMMV.

I asked gpt to chase down the studies that support this assertion. Results follow. If the studies behind this claim aren’t considered in the ai search below, please share.

As always, if you’re unlucky enough to be the ‘1 in 2000’ to experience a rare side (severe) effect, you don’t get a do-over. So a good reason to be cautious.

The claim in that post is considerably stronger than the evidence supports. I can find solid evidence that bisphosphonates can produce long-lasting suppression of bone remodeling in alveolar bone, and that drug remains associated with the skeleton for years. I cannot find evidence showing that an osteoporosis-dose course causes the bone around the teeth to become permanently damaged or permanently inferior for dental work.

The distinction matters: persistent pharmacologic effect ≠ permanent structural damage.

Where the claim probably comes from

Evidence What it actually shows
Very long skeletal retention Alendronate binds hydroxyapatite and has an estimated terminal skeletal half-life of >10 years. But that figure is a pharmacokinetic estimate; a later pharmacology review cautions that the often-quoted 10-year number is extrapolated and shouldn’t be interpreted too literally. Stored drug is largely inactive until the bone surface is resorbed. (dailymed.nlm.nih.gov)
Alveolar remodeling suppression In beagles given clinically relevant alendronate for 3 years, alveolar mandibular turnover was about 75% lower, and focal microscopic necrotic areas occurred in 25–33% of treated animals versus none of the controls. Importantly, none developed clinically exposed jaw bone. This is probably one of the strongest experiments supporting concern specifically about alveolar bone. (pmc.ncbi.nlm.nih.gov)
Abnormal human jaw tissue in MRONJ Biopsies from people who had actually developed bisphosphonate-related ONJ show abnormal remodeling, thicker trabeculae, fewer Haversian canals, osteocyte loss, etc. But these are selected diseased patients, often receiving high oncology doses, so they cannot establish that ordinary bisphosphonate users have the same pathology. (pubmed.ncbi.nlm.nih.gov)
Orthodontic effects Human case reports and small cohorts show slower tooth movement and sometimes sclerotic alveolar changes. A 2026 umbrella review says the effect on orthodontic tooth movement is consistent, but human evidence remains sparse and weak. (link.springer.com)

The beagle study is particularly interesting because the alveolar portion of the jaw normally remodels much faster than non-alveolar mandibular bone. That provides a plausible mechanism for why the jaw is unusually vulnerable to potent antiresorptive therapy. But it still does not establish irreversible damage. (pmc.ncbi.nlm.nih.gov)

Human evidence is much more reassuring

There are several studies that actively cut against the “your dental bone is compromised forever” interpretation.

A randomized trial of 335 people with periodontal disease treated for two years with weekly alendronate found no excess alveolar bone loss or ONJ; among subjects with low mandibular BMD, alendronate actually reduced alveolar bone loss. (pubmed.ncbi.nlm.nih.gov)

A radiographic study of women treated with bisphosphonates for an average of roughly 4–5 years found no significant alteration of alveolar or basal jaw trabecular structure compared with untreated women. (pubmed.ncbi.nlm.nih.gov)

More directly relevant to dental surgery, a prospective study of women with osteoporosis taking alendronate or yearly zoledronic acid found that tooth-extraction sockets and overlying mucosa healed successfully; by 90 days all patients had mucosal healing, without requiring discontinuation of bisphosphonate treatment. (pubmed.ncbi.nlm.nih.gov) Another prospective study of 132 oral-bisphosphonate users did find slower socket healing after >5 years of treatment, but no cases of ONJ occurred. (pubmed.ncbi.nlm.nih.gov)

And the major randomized zoledronic-acid osteoporosis trial is especially useful here: 7,714 women, zoledronic acid 5 mg yearly versus placebo for three years. There was one potential ONJ case in the zoledronic-acid group and one in the placebo group; both resolved. (pubmed.ncbi.nlm.nih.gov)

What about future implants?

This is probably the most important implication of the post.

The 2025 International ONJ Taskforce systematically reviewed implant outcomes in osteoporosis patients receiving antiresorptives. Their conclusion was that current evidence does not show increased dental-implant failure, and they suggest that antiresorptive treatment does not have to be stopped before an implant. They explicitly say implants can generally be placed in osteoporosis patients receiving bisphosphonates, although the evidence quality for implant outcomes is low. (pubmed.ncbi.nlm.nih.gov)

There is nevertheless a small MRONJ signal. The accompanying 2025 meta-analysis found a pooled post-implant MRONJ rate of about 0.5% among antiresorptive-treated osteoporosis patients; one adjusted cohort suggested bisphosphonate exposure added about 3 MRONJ cases per 1,000 patients. Implant failure itself was not increased in the primary patient-level analysis. (pubmed.ncbi.nlm.nih.gov)

Another 2025 meta-analysis illustrates how uncertain the evidence remains: it found an implant-level failure RR of 1.74, but no patient-level increase (RR 1.01), no significant increase in marginal bone loss, and rated the evidence very low certainty. (pubmed.ncbi.nlm.nih.gov)

The “permanent” part does not hold up

There is excellent evidence that effects persist after treatment stops. In FLEX, after five years of alendronate followed by five years off treatment, bone-turnover markers gradually rose toward pretreatment levels. (pubmed.ncbi.nlm.nih.gov) With zoledronic acid, after three annual doses, measurable antiresorptive effects persisted for another three years, but BMD began declining and PINP rose—again demonstrating an offset of effect, rather than permanent suppression. (pmc.ncbi.nlm.nih.gov)

So I would rewrite the post’s assertion this way:

Bisphosphonates become incorporated into bone and can influence remodeling for years after treatment. Because alveolar bone has unusually high turnover, dental extraction and implant surgery carry a small persistent MRONJ risk, particularly with prolonged treatment and high oncology doses. There is no evidence that osteoporosis-dose bisphosphonates permanently render alveolar bone unhealthy or permanently compromise a patient’s ability to receive dental implants.

That’s substantially different from “you are stuck for life.”

For osteoporosis-dose zoledronic acid specifically, the evidence is substantially more reassuring than the post implies. The very alarming jaw literature is disproportionately derived from cancer patients receiving much larger and more frequent IV doses. AAOMS currently estimates MRONJ risk from bisphosphonates used for osteoporosis at roughly 0.02–0.04% overall, while still acknowledging that invasive dental procedures and longer exposure increase it. (aaoms.org)

Confidence: high that the “permanently altered and compromised for life” statement is not supported by the available human evidence. The more defensible claim is long-lived alteration of remodeling with a small, nonzero dental-surgical risk.

If useful, I can next dig specifically into zoledronic acid/Reclast and dental implants after 1, 2, or 3 annual 5-mg infusions; that would narrow this considerably to the exposure pattern most relevant to osteoporosis treatment.

This paper references earlier reports of terminal life of 11 years. This means complete elimination at more than 20 years. If you are starting bis therapy in your 70’s, that’s essentially lifelong persistance, if we assume a 90+ year lifespan. Of course one may claim it’s excessive extrapolation and furthermore perhaps it doesn’t matter for dental work like implants, or as suggested the downside is statistically tiny, but it’s still not a positive in my book. I’d rather not have it in the bones around my teeth for possibly 20+ years. Like I admitted, it’s probably excessive concern, but I am squicked out by bone alterations that last multiple decades in my late years, as to me it spells “lifelong”.

Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates

https://pubmed.ncbi.nlm.nih.gov/17523760/

“Results: Data were sufficient for analysis of pharmacokinetics in 11 patients. A mean t((1/2)gamma) of approximately 11 years was reported previously, based on analysis of data between days 240 and 540.”

Yes, you can lose teeth even with the best of care. The best and most expensive option is a dental implant. My dental surgeon’s list of no-no drugs includes bisphosphonates.

2 Likes

EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial

Thanks for the encouraging preliminary good news for ApoE4 carriers. It would be interesting to know how long the benefits persist after stopping rapa. 1mg/d forever isn’t ideal. A well-persisting effect could also make this approach an option for those who likely shouldn’t be doing ongoing (even weekly) rapa longevity protocols (e.g., fragile-x premutation women).

An updated posted by Dr. Fraser:

2 Likes

As a long term update - here is my generic advice and focus on high yield items for those concerned about neurodegenerative decline, especially those with an ApoE4.

Watch this video from Dr. Stanfield, whether you have an ApoE4 of not:

If you don’t know your ApoE status, self order here: Genetic test Kits - FIDALAB with Code FRASER25 ApoE genotype for $50 (I make no money from this, this is purely a patient discount)

For ApoE4’s especially, but for everyone, consider:

For those with ApoE4’s prioritize:
Yearly PREMAZ test
MRI that includes Neuroquant at baseline and repeat at 3 year intervals if no significant concerns; more frequent if there are concerns.
Baseline Beta Amyloid 42:40 and p-Tau-217
Consider low dose lithium, GLP-1, SGLT2-I, Telmisartan, Statins that get into the brain, Ezetimibe, Exercise, Sleep optimization, Nutritarian diet with added fish with high omega 3’s (favor Black Cod - note CostCo is a good source or NWWildfoods)

There are a hundred other things that one might do, but this is my updated summary of what I currently prioritize and has risen the the top of the range of possibilities.

9 Likes

Hi Grant,

Thank you for this info! A couple questions/ comments:

wondering wny you are peferring Empa over Dapa / Cana.

Also, the Amazon link for the Plasmologesn didn’t work when I tried it.

Thanks- Sally

I had never heard of the Nutritarian Diet - so wanted more information:

PRO-21 exclusions

From the Nutritarian Video Dr. Fraser posted:

Top Doctors on Food, Healing, and Hope

I. Executive Summary

This panel discussion, convened under the auspices of the Physicians Committee for Responsible Medicine at the National Health Association Conference, examines the clinical application of whole-food, plant-based (WFPB) and “nutritarian” diets for chronic disease mitigation, athletic longevity, and neurobehavioral recovery. The clinical thesis asserts that shifting from a standard Western dietary pattern—characterized by ultra-processed foods, refined carbohydrates, saturated lipids, and animal protein—to an unrefined, micronutrient-dense plant portfolio significantly modulates all-cause mortality, cardiovascular pathology, and systemic inflammation. The panelists, comprising lifestyle medicine and sports medicine clinicians, argue that dietary categorization requires clinical precision. They differentiate between an unsupplemented, nutrient-poor vegan diet and targeted whole-food regimens designed to maximize phytochemical density (specifically through cruciferous vegetables, alliums, legumes, fungi, berries, and seeds).

A primary clinical tension explored is the trade-off between short-term athletic adaptation and long-term cardiometabolic survival. Panelists note that extreme hypertrophic mass and high-protein, animal-dense or ketogenic protocols common in collision sports (e.g., NFL linemen) accelerate coronary atherosclerosis, microvascular hypoperfusion, and tendinopathy, leading to significantly shortened lifespans compared to non-collision, endurance, or movement-centric athletes. Conversely, evidence indicates that isocaloric, protein-adequate plant-based regimens preserve lean body mass and aerobic endurance while attenuating vascular inflammation and endothelial oxidative stress.

Addressing public health implementation, the discussants evaluate food addiction through a neurobiological lens. They model ultra-processed hyper-palatable formulations (combinations of free sugars, saturated fats, and sodium) as central nervous system dopaminergic disruptors requiring prolonged neurochemical recalibration. A clinical debate emerges between gradual risk-reduction strategies (“baby-stepping”) and total enforced abstinence. The panelists favor structured immersion and intensive lifestyle intervention models—such as shared medical appointments, residential retreats, and institutional “choice architecture” alterations—to reset hedonic tone and sustain long-term behavioral compliance. Finally, while recognizing the profound predictive validity of population modeling studies demonstrating an 8- to 13-year life expectancy extension via dietary optimization, the clinicians emphasize that individual biological reversibility depends on baseline vascular damage, epigenetic aging, and adherence thresholds.

II. Insight Bullets

  • Dr. Megan Greger defines a clinically effective plant-predominant dietary pattern as consisting of minimally processed fruits, vegetables, legumes, whole grains, nuts, seeds, mushrooms, and spices, devoid of animal products, refined seed oils, added sodium, and processed sugars.
  • Dr. Joel Fuhrman argues that standard “whole-food plant-based” terminology lacks clinical specificity and promotes the “Nutritarian” model, which prioritizes nutrient-to-calorie ratios and high-phytochemical plant groups.
  • The Physicians Committee for Responsible Medicine promotes evidence-based lifestyle medicine interventions to prevent and reverse cardiometabolic conditions.
  • The Kellen Foundation implements community-level lifestyle medicine interventions across diverse socioeconomic cohorts using standardized nutritional education frameworks.
  • A vegan diet reliant on ultra-processed carbohydrates, refined oils, and sodium frequently exacerbates acne, fatigue, visceral adiposity, and metabolic dysregulation due to micronutrient dilution and glycemic volatility.
  • Dr. Fuhrman posits that broad variance in human longevity curves is heavily determined by modifiable lifestyle inputs, which can compress morbidity and narrow the lifespan distribution toward maximal genetic potential.
  • Dr. Stephan Esser notes that elite athletic training can temporarily mask underlying vascular and metabolic pathology induced by hypercaloric or carnivorous diets, but chronic degenerative disease manifests post-retirement.
  • According to the National Institute for Occupational Safety and Health (Baron et al., 1994 / CDC), retired NFL linemen exhibit a 52% higher risk of cardiovascular mortality compared to the general male population and triple the risk of non-linemen peers due to extreme body mass and diet-induced cardiometabolic strain.
  • Non-collision professional athletes maintaining lower adiposity and engaging in endurance- or agility-based sports demonstrate enhanced career longevity when adhering to micronutrient-rich, plant-predominant nutrition.
  • Systemic hypercholesterolemia and elevated low-density lipoprotein particles impair microvascular perfusion and alter extracellular matrix remodeling, directly increasing the risk of tendinopathies and tendon ruptures.
  • Sumo wrestlers consuming high-calorie, hyper-protein diets experience severely truncated life expectancies (frequently dying in their late 50s) driven by metabolic syndrome and premature coronary artery disease.
  • Global Burden of Disease modeling published in PLoS Medicine by Fadnes et al., 2022 demonstrates that transitioning from a typical Western diet to an optimized plant-predominant diet at age 20 increases life expectancy by approximately 10.7 years for men and 13.0 years for women.
  • The same modeling by Fadnes et al., 2022 indicates that adopting an optimized dietary portfolio at age 60 yields an estimated 8.0 to 8.8 years of increased life expectancy, and at age 80 adds approximately 3.4 years of healthy survival.
  • Dr. Fuhrman asserts that aggressive, comprehensive lifestyle modification can restore motor balance and functional cognitive capacity in early-stage neurodegenerative decline.
  • Dr. Esser highlights that modifiable behaviors governed by physical activity, lifestyle choices, and nutritional intake serve as the primary determinants of clinical healthspan.
  • Environmental choice architecture within schools, medical centers, and municipal venues currently defaults to ultra-processed, calorie-dense foods, impeding long-term dietary adherence.
  • The American College of Lifestyle Medicine advocates for therapeutic lifestyle interventions as the primary treatment modality for chronic lifestyle-related diseases.
  • Peer-to-peer coaching and shared medical appointment models demonstrate superior clinical outcomes over standard 10-to-15-minute primary care encounters by providing sustained accountability and community reinforcement.
  • Ultra-processed, hyper-palatable foods containing engineered ratios of salt, sugar, and fat induce dopamine receptor downregulation akin to classical substance use disorders.
  • Dr. Fuhrman contends that gradual harm-reduction approaches (“baby-stepping”) frequently fail in severe food addiction due to intermittent reinforcement of hedonic cravings, advocating instead for acute, enforced abstinence.
  • Resetting central nervous system dopamine sensitivity and extinguishing food-cue cravings typically requires an intensive 3-month intervention period, with neurobehavioral consolidation taking 6 to 12 months.
  • Severe physician burnout within standard fee-for-service systems—characterized by excessive patient panels (e.g., 5,000 patients) and compressed visit times—limits the delivery of preventive lifestyle medicine.
  • The National Health Association supports research and education on whole-food plant-based nutrition, water-only fasting, and disease reversal.
  • The Culinary Institute of America has integrated nutritional science into culinary training via initiatives such as “The Protein Flip,” teaching chefs to rebalance plates with plant proteins and complex whole foods.
  • Replacing maladaptive emotional eating with deliberate somatic coping mechanisms—including resistance exercise, outdoor endurance activities, and sleep hygiene—attenuates hypothalamic-pituitary-adrenal axis hyperactivation.
  • Plant-predominant dietary frameworks supply adequate amino acid profiles and total caloric density to sustain elite athletic recovery, mitochondrial biogenesis, and physical endurance without compromising lean tissue mass.
  • Structural societal interventions—such as institutional food policy reforms and municipal wellness initiatives—must augment individual behavioral modification to reverse escalating national obesity and metabolic disease prevalence.

III. Adversarial Claims & Evidence Table

Claim from Video Speaker’s Evidence Scientific Reality (Current Data) Evidence Grade (A-E) Verdict
Switching from a standard Western diet to an optimized plant-rich diet at age 20 increases life expectancy by 10 to 13 years, and at age 60 by ~8 years. Global Burden of Disease (GBD) 2019 modeling simulation data. Validated modeling study utilizing GBD data (Fadnes et al., 2022, PLoS Med). Largest gains derived from increased legumes, whole grains, nuts, and reduction in red/processed meats. Level A Strong Support
Professional NFL linemen suffer the shortest life expectancy of any North American athletic group due to forced hypertrophy and hypercaloric diets. NIOSH NFL occupational mortality cohort study cited by Dr. Fuhrman. NIOSH cohort analysis (Baron et al., 1994 / CDC) confirmed linemen had a 52% higher risk of cardiovascular mortality compared to the general population and a 3-fold higher risk than non-linemen players. However, overall NFL players had lower all-cause mortality (SMR 0.54) due to a healthy worker effect; the claim of “shortest lifespan of anyoccupation in North America” is an overstatement. Level C Plausible
Elevated serum cholesterol directly correlates with tendon pathology, structural tendon degradation, and micro-tears. Dr. Esser’s clinical experience and referenced laboratory/human literature. Systematic reviews and meta-analyses (Tilley et al., 2015, Br J Sports Med; Zhao et al., 2020) establish that individuals with Achilles tendinopathy and tendon ruptures exhibit significantly higher total cholesterol, LDL-C, and triglycerides, driven by extracellular matrix lipid accumulation and tendon microvascular ischemia. Level A Strong Support
Intensive plant-based lifestyle interventions can arrest or reverse early-stage dementia and restore lost neuromotor balance. Anecdotal cases in Dr. Fuhrman’s clinical practice over 35 years. A Phase II randomized controlled trial (Ornish et al., 2024, Alzheimers Res Ther) demonstrated that a comprehensive lifestyle intervention (plant-based diet, exercise, stress management, supplements) improved cognitive and functional metrics (ADAS-Cog, CDR-SB) and plasma Aβ42/40 ratios in mild cognitive impairment and early Alzheimer’s. However, claims of complete “reversal” and balance restoration remain small-scale and preliminary. Level B Plausible
Severe food addiction cannot be resolved via incremental changes (“baby-stepping”); it requires strict enforced abstinence to reset dopamine receptors. Addiction medicine withdrawal model and Dr. Fuhrman’s residential retreat observations. Neurobiological studies verify downregulation of striatal D2 dopamine receptors in response to hyper-palatable ultra-processed foods (Volkow et al., 2017). However, clinical trials in eating disorders and ultra-processed food addiction demonstrate that rigid abstinence can trigger binge-eating relapse and orthorexic behaviors; evidence directly comparing mandatory abstinence vs. structured flexible moderation remains equivocal (Thompson et al., 2025, Front Psychiatry). Level E Speculative
Neurotransmitter sensitivity and craving drives take 3 months of strict abstinence to recalibrate in food addiction. Extrapolation from the neurobiology of substance use disorders (e.g., cocaine, alcohol, nicotine). Functional neuroimaging confirms that dopaminergic and opioid receptor densities normalize over 12–24 weeks of sustained abstinence from specific addictive reinforcers. Human neuroimaging data quantifying this exact 3-month timeline specifically for food-cue striatal reactivity remains unverified in controlled longitudinal trials. Level D (Translational Gap) Speculative
Plant-based athletes achieve superior aerobic capacity and equivalent strength/power performance compared to omnivorous athletes. Clinical observations of elite endurance and tennis athletes (e.g., Venus Williams, Novak Djokovic). Systematic reviews and meta-analyses (Neville et al., 2024, Br J Nutr; Monteyne et al., 2021, Sports Med) show that plant-based diets improve or match aerobic performance (VO2 max, endothelial perfusion) and support equivalent skeletal muscle hypertrophy and strength when total daily protein is matched (≥1.6 g/kg/day). Level A Strong Support

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Domain Clinical Action Dosing / Target Primary Endpoint
Cardiometabolic Optimization Transition from Western dietary pattern to unrefined whole plant foods (legumes, whole grains, vegetables, nuts). Daily target: ≥3 servings legumes, ≥3 servings whole grains, ≥5 servings vegetables, 30–50 g nuts/seeds; saturate fiber at ≥45 g/day. Reduction of serum ApoB (<70 mg/dL), LDL-C (<70 mg/dL), hs-CRP (<1.0 mg/L), and 8–13 year extension in projected life expectancy (Fadnes et al., 2022).
Microvascular & Tendon Health Atherogenic dyslipidemia control via saturated fat elimination and soluble viscous fiber titration. Limit saturated fatty acids to <5% of total caloric intake; eliminate trans fats; maintain plant sterols at >2 g/day. Normalization of serum lipid parameters; attenuation of tendinous xanthomatous lipid infiltration and tendon rupture risk (Tilley et al., 2015).
Athletic Endurance & Performance Nitrogen-balanced whole-food plant diet with high complex carbohydrate loading. Target 1.6–2.2 g/kg/day protein via varied plant sources (soy, mycoprotein, lentils, hemp) and 6–10 g/kg/day complex carbohydrates. Maintenance of skeletal muscle protein synthesis (MPS) equivalent to whey/meat; enhanced skeletal muscle glycogen repletion and flow-mediated dilation (Neville et al., 2024).
Cognitive Decline Mitigation Multidomain intensive lifestyle intervention in mild cognitive impairment (MCI). Whole-food plant diet + 30 min/day aerobic exercise + 60 min/day stress reduction + 3x/week group support + targeted supplementation (B12, D3, EPA/DHA). Statistically significant improvements in CDR-SB and ADAS-Cog scores; stabilization of plasma Aβ42/40 ratio at 20 weeks (Ornish et al., 2024).

Experimental Tier (Level C/D Evidence - High Safety Margin)

  • Phytochemical-Dense Portfolio (“Nutritarian” Protocol): Consume a daily baseline of the “GBOMBS” portfolio (Greens, Beans, Onions, Mushrooms, Berries, Seeds). Proposed mechanism: sulforaphane, allicin, and beta-glucans induce Nrf2 transcription, inhibit HDAC, and suppress tumor angiogenesis via VEGF downregulation. Monitoring: Serial high-sensitivity C-reactive protein (hs-CRP), fasting insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
  • Supervised Habituation Reset for Food Addiction: Implement a structured 12-week dietary period eliminating hyper-palatable ultra-processed foods (refined flours, isolated fats, concentrated sugars). Proposed mechanism: resensitization of central D2 dopamine receptors within the ventral striatum and reduction of nucleus accumbens cue reactivity. Monitoring: Yale Food Addiction Scale (YFAS 2.0) score, binge frequency logs, and resting sympathetic tone.
  • Non-Pharmacologic Somatic Stress Inoculation: Replace hedonic food-reward seeking with protocolized physical exertion (zone 2 aerobic exercise, resistance training) and nature immersion. Proposed mechanism: attenuation of hypothalamic-pituitary-adrenal (HPA) axis cortisol secretion and normalization of sympathetic tone. Monitoring: Heart rate variability (HRV, rMSSD), diurnal salivary cortisol, and Pittsburgh Sleep Quality Index (PSQI).

Red Flag Zone (Debunked, High-Risk, or Contraindicated)

Unmonitored Extreme Hypertrophic Regimens (e.g., Heavyweight Collision Athletes): Consuming chronic hypercaloric animal-dense diets (e.g., >5,000 kcal/day with excessive saturated fats and cholesterol) to force supraphysiological body mass. Clinical Risk: Accelerates systemic atherogenesis, severe endothelial dysfunction, premature coronary artery disease, obstructive sleep apnea, and significantly elevated cardiovascular mortality (Baron et al., 1994).

Junk-Food Veganism (Refined Plant Diets): Eliminating animal products while relying primarily on ultra-processed vegan substitutes, refined seed oils, isolated starches, and liquid sugars. Clinical Risk: Induces high glycemic variability, hepatic de novo lipogenesis, visceral adiposity, hypertriglyceridemia, and elevated risk of non-alcoholic fatty liver disease (MASLD) identical to or exceeding standard omnivorous diets.

Rigid Enforced Dietary Abstinence in Unscreened Eating Disorder Cohorts: Imposing absolute, binary dietary bans (“forbidden foods”) on patients with binge-eating disorder or bulimia nervosa without psychiatric supervision. Clinical Risk: High incidence of psychological distress, orthorexia nervosa, rebound binge episodes, and treatment attrition (Thompson et al., 2025).

V. Technical Mechanism Breakdown

[ Ultra-Processed Diet (SFA, Refined Sugars, Sodium) ] │ ├─► Systemic Hyperlipidemia (ApoB/LDL-C) ──► Endothelial Dysfunction & Tendon Extracellular Lipid Infiltration ├─► Striatal Dopamine Overstimulation ──► D2 Receptor Downregulation ──► Hedonic Cravings & Food Addiction └─► Chronic Systemic Inflammation (hs-CRP) ──► Microvascular Rarefaction & Neurodegeneration

1. Striatal Neuroadaptation and Hedonic Allostasis in Food Addiction

The neurobiology underlying ultra-processed food addiction involves artificial industrial formulations that combine refined carbohydrates (free sucrose, high-fructose corn syrup) and concentrated lipids at ratios not found in nature. Ingestion induces rapid gastric emptying and immediate postprandial glucose-insulin spikes, triggering supra-physiological surges of extracellular dopamine within the mesolimbic dopamine system—specifically the nucleus accumbens (NAc) and ventral tegmental area (VTA).

Chronic, repeated exposure drives down-regulation of post-synaptic striatal dopamine D2 receptors (D2RD2​R), analogous to the neuroadaptations observed in substance use disorders. This receptor deficiency manifests as an allostatic shift in the brain’s reward threshold: physiological, nutrient-dense whole foods (e.g., raw cruciferous vegetables, whole grains) fail to elicit sufficient dopaminergic tone, inducing chronic hypodopaminergia, anhedonia, and compulsive food-seeking. The 12-week timeline posited for abstinence protocols reflects the biological latency required for neurogenesis, transcriptional remodeling of ΔFosBΔFosB, and cellular upregulation of striatal D2RD2​R availability to re-establish physiological baseline sensitivity.

2. Endothelial Perfusion, Microvascular Rarefaction, and Lipid-Mediated Tendinopathy

The correlation between atherogenic dyslipidemia and musculoskeletal injury involves distinct vascular and structural mechanisms:

  • Microvascular Perfusion Deficits: Elevated circulating apolipoprotein B (ApoB)-containing lipoproteins infiltrate the subendothelial space of microvascular capillary beds supplying poorly vascularized connective tissue (e.g., the watershed region of the Achilles tendon and supraspinatus tendon). Enzymatic and non-enzymatic oxidation yields oxidized low-density lipoprotein (oxLDL), which binds scavenger receptors (CD36, LOX-1) on endothelial cells. This interaction triggers protein kinase C activation and upregulates NADPH oxidase, generating reactive oxygen species (ROS) that uncouple endothelial nitric oxide synthase (eNOS). The resulting deficiency in bioactive nitric oxide (NONO) impairs flow-mediated vasodilation, producing chronic microvascular ischemia within tendon sheaths.
  • Extracellular Matrix (ECM) Disruption: Hypercholesterolemia drives direct lipid deposition within tenocytes and the interstitial extracellular matrix. Accumulated oxLDL promotes tenocyte apoptosis and stimulates matrix metalloproteinases (specifically MMP-1, MMP-2, and MMP-9) while suppressing tissue inhibitors of metalloproteinases (TIMPs). This enzymatic shift degrades type I collagen fibers and alters tendon ultrastructure, resulting in micro-tears, collagen disorganization, and failure to repair under repetitive mechanical tensile loads.

3. Hypertrophic Signaling vs. Vascular Longevity in Athletes

The dichotomy between athletic mass accumulation and lifespan hinges on the modulation of the nutrient-sensing kinase mammalian target of rapamycin complex 1 (mTORC1) and insulin-like growth factor 1 (IGF-1):

  • mTORC1 Hyperactivation: Diets high in animal protein, particularly rich in essential branched-chain amino acids (leucine, isoleucine, valine) and sulfur-containing amino acids (methionine), potently stimulate Sestrin2 and the Rag GTPase signaling cascade, driving constitutive mTORC1 phosphorylation. While this maximizes ribosomal biogenesis and muscle protein synthesis, chronic mTORC1 activation suppresses cellular autophagy and mitophagy. This prevents the clearance of damaged mitochondria, aggregates of misfolded proteins, and senescent cells.
  • Accelerated Vascular Aging: In collision athletes requiring high caloric loads, sustained elevated IGF-1 and hyperinsulinemia drive vascular smooth muscle cell proliferation and osteogenic differentiation, accelerating arterial calcification and pulse-wave velocity. When paired with high saturated fat intake, the downstream atherogenic burden precipitates early-onset coronary plaque instability, providing a mechanistic basis for the excess cardiovascular mortality observed in super-heavyweight athletes.

4. Neuroinflammation and the Amyloid-Microbiome Axis in Cognitive Decline

The reversal or slowing of cognitive impairment via intensive plant-predominant lifestyle modifications operates through metabolic, vascular, and gut-brain axes:

  • Amyloid Homeostasis: High-fat, hypercholesterolemic diets disrupt blood-brain barrier (BBB) integrity via the receptor for advanced glycation end products (RAGE) pathway, increasing peripheral circulating Aβ influx into the brain parenchyma while decreasing low-density lipoprotein receptor-related protein 1 (LRP1)-mediated clearance. A whole-food plant diet reduces circulating saturated lipids and systemic oxidative stress, promoting clearance and shifting the plasma Aβ42/Aβ40 ratio toward neuroprotective thresholds.
  • Microbiome-Mediated Neuroprotection: Unrefined dietary plant fibers and resistant starches undergo anaerobic fermentation by colonic taxa (e.g., Faecalibacterium prausnitzii, Roseburia), yielding short-chain fatty acids (SCFAs), predominantly butyrate, acetate, and propionate. Butyrate crosses the gut barrier, enters systemic circulation, and acts as an endogenous histone deacetylase (HDAC) inhibitor. It upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus, strengthens tight junction claudin-5 and occludin expression at the BBB, and suppresses microglial M1 pro-inflammatory polarization, attenuating neuroinflammatory synaptic pruning.

Actionable Execution & Verification Schedule

  1. Baseline Biochemical Staging (Week 0): Obtain an advanced cardiometabolic panel: NMR LipoProfile (quantifying LDL Particle Number and Small Dense LDL), ApoB, fasting insulin, HbA1c, hs-CRP, comprehensive metabolic panel, and fasting lipid panel. Screen for food addiction pathology utilizing the standardized Yale Food Addiction Scale (YFAS 2.0).
  2. Phase 1 Dietary Recalibration (Weeks 1–4): Eliminate all ultra-processed foods, refined carbohydrates, added vegetable seed oils, and saturated animal fats. Construct daily intake exclusively around the verified plant portfolio: minimum 45 g/day total dietary fiber, focusing on legumes (lentils, chickpeas, black beans), whole grains (rolled oats, quinoa, farro), cruciferous vegetables (sulforaphane precursors), alliums, and intact seeds (flax, chia, walnut).
  3. Phase 2 Neurobehavioral & Training Consolidation (Weeks 5–12): Structure daily somatic stress mitigation (30 minutes of aerobic zone 2 cardiovascular output; 15 minutes of structured parasympathetic down-regulation via breathwork or meditation). If athletic hypertrophy or endurance is required, titrate plant protein to 1.6–2.0 g/kg/day utilizing whole-food matrices (tempeh, edamame, concentrated lentil purees, seitan) without resorting to isolated ultra-processed powders.
  4. Endpoint Laboratory Verification (Week 12): Re-test ApoB, lipid panel, hs-CRP, and fasting insulin. Target clinical metrics: ApoB <70 mg/dL, hs-CRP <0.8 mg/L, HOMA-IR <1.5. Re-administer YFAS 2.0 to quantify objective suppression of hedonic food-cue reactivity.

Produced by Gemini 2.5 Pro

2 Likes

Sorry on the link, I’ve fixed that.

They also have a plasmalogen test that is on sale for $49 right now (1/2 price) but does require a blood draw.

On the SGLT2-i

Drug Brain/Serum Ratio (AUC) Notes
Empagliflozin ~0.5 Highest among the common agents in the cited data
Dapagliflozin ~0.3 —
Canagliflozin ~0.3 Serum levels ~10 µM can yield brain levels ~3 µM (enough for some off-target effects in models)

It just gets more into the brain. The reason why I used to prefer dapagliflozin was purely for cost as it is around $15 for 90 days from CostPlusDrugs. The Empagliflozin continues to be much more expensive, but from Canadian Prescription DrugStore is is <$1/day, but now we have the issue of whether one can get it into the country.

5 Likes